Optimizing rWTC-MBTA Vaccine Formulations, Dosing Regimens, and Cryopreservation Techniques to Enhance Anti-Metastatic Immunotherapy
International Journal of Molecular Sciences,
Год журнала:
2025,
Номер
26(3), С. 1340 - 1340
Опубликована: Фев. 5, 2025
Metastatic
cancer
poses
significant
clinical
challenges,
necessitating
effective
immunotherapies
with
minimal
systemic
toxicity.
Building
on
prior
research
demonstrating
the
rWTC-MBTA
vaccine’s
ability
to
inhibit
tumor
metastasis
and
growth,
this
study
focuses
its
translation
by
optimizing
vaccine
composition,
dosing
regimens,
freezing
techniques.
The
formula
components
included
three
TLR
ligands
(LTA,
Poly
I:C,
Resiquimod)
an
anti-CD40
antibody,
which
were
tested
in
melanoma
triple-negative
breast
(TNBC)
models.
formulations
categorized
as
rWTC-MBT
(Mannan-BAM
LTA,
Resiquimod),
rWTC-MBL
(LTA),
rWTC-MBP
I:C),
rWTC-MBR
(Resiquimod).
In
models,
all
exhibited
efficacy
that
was
comparable
of
full
vaccine,
while
“colder”
TNBC
multiple
or
Resiquimod
alone
performed
best.
Vaccine-induced
activation
dendritic
cell
(DC)
subsets,
including
conventional
DCs
(cDCs),
myeloid
(mDCs),
plasmacytoid
(pDCs),
accompanied
CD80+CD86+
population
induction,
suggesting
robust
innate
immune
stimulation.
An
initial
three-dose
schedule
followed
booster
doses
(3-1-1-1
3-3-3-3)
reduced
metastatic
burden
effectively.
Gradual
(DMSO-based
preservation)
maintained
efficacy,
underscoring
importance
intact
structure.
These
findings
highlight
potential
simplified
formulations,
optimized
dosing,
techniques
developing
practical,
scalable
for
cancers.
Язык: Английский
Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders
Clinical Reviews in Allergy & Immunology,
Год журнала:
2025,
Номер
68(1)
Опубликована: Фев. 11, 2025
Язык: Английский
Antibody-drug conjugate combinations in cancer treatment: clinical efficacy and clinical study perspectives
Frontiers in Pharmacology,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 21, 2025
Antibody-drug
conjugates
have
emerged
as
a
promising
cancer
treatment,
combining
targeted
delivery
of
cytotoxic
agents
with
the
specificity
monoclonal
antibodies.
Despite
their
potential,
ADCs
face
limitations
such
resistance
and
off-target
effects.
To
enhance
efficacy,
are
increasingly
being
combined
other
therapeutic
strategies,
including
immune
checkpoint
inhibitors,
chemotherapy,
small-molecule
anti-angiogenic
agents,
CAR-T
cell
therapies.
These
combination
therapies
aim
to
overcome
mechanisms,
improve
tumor
targeting,
boost
responses.
Clinical
studies
shown
that
combinations
can
significantly
response
rates
progression-free
survival
across
various
cancers.
This
review
explores
clinical
key
studies,
challenges,
future
perspectives
in
therapy.
Язык: Английский
Global research progress in antibody-drug conjugates for solid tumors: Bibliometrics and visualized analysis
Human Vaccines & Immunotherapeutics,
Год журнала:
2025,
Номер
21(1)
Опубликована: Фев. 27, 2025
Recently,
the
use
of
antibody-drug
conjugates
(ADCs)
in
research
and
management
solid
tumors
has
increased,
making
them
a
key
focus
field
oncology.
In
this
study,
we
performed
comprehensive
literature
review
ADCs
tumor
treatment.
We
retrieved
data
from
Web
Science
Core
Collection
(WoSCC).
Following
retrieval,
conducted
thorough
bibliometric
knowledge-mapping
analysis
collected
articles.
There
was
rapid
growth
number
annual
publications
field.
The
United
States
had
highest
publication
volumes
led
ADC
for
tumors.
Additionally,
Dana-Farber
Cancer
Institute
output,
G.
Curigliano
identified
as
most
productive
author.
journal
"Cancers"
publishing
on
Furthermore,
clustering
terms
such
"breast
cancer,"
"targeted
therapy,"
"bladder
"ovarian
"expression,"
"drug
delivery"
emerged
progressed.
six
themes
by
co-citation
analysis,
involving
application
four
breast
cancer,
well
design,
mechanisms,
strategies
reducing
cytotoxicity.
At
same
time,
based
papers
that
have
experienced
citation
burst
recently,
explored
future
development
trends
Overall,
our
inaugural
provides
systematic
framework
to
guide
studies
Therefore,
facilitating
promoting
further
area.
Язык: Английский
Navigating the Landscape of Resistance Mechanisms in Antibody–Drug Conjugates for Cancer Treatment
Targeted Oncology,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 15, 2025
Язык: Английский
Advancements in antibody-drug conjugates as cancer therapeutics
Jung Yin Fong,
Zhixin Phuna,
D. Chong
и другие.
Journal of the National Cancer Center,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Safety and efficacy of antibody-drug conjugates plus immunotherapy in solid tumours: A systematic review and meta-analysis
Cancer Treatment Reviews,
Год журнала:
2024,
Номер
131, С. 102847 - 102847
Опубликована: Окт. 18, 2024
Язык: Английский
Lung Toxicity Occurring During Enfortumab Vedotin Treatment: From a Priming Case Report to a Retrospective Analysis
Grégoire Desimpel,
François Zammit,
Sarah Lejeune
и другие.
Pharmaceuticals,
Год журнала:
2024,
Номер
17(11), С. 1547 - 1547
Опубликована: Ноя. 18, 2024
Enfortumab
vedotin
(EV)
is
an
antibody-drug
conjugate
(ADC)
that
combines
monomethyl
auristatin
E
(MMAE),
a
potent
cytotoxic
agent,
with
monoclonal
antibody
targeting
Nectin-4.
It
has
emerged
as
promising
therapy
for
metastatic
urothelial
carcinoma
(mUC),
either
monotherapy
or
in
combination
pembrolizumab,
improving
significantly
the
overall
survival
of
these
patients.
EV
associated
common
adverse
events,
including
skin
reactions,
glucose
imbalance,
and
peripheral
neuropathy,
which
are
usually
mild
severity
easily
manageable.
Язык: Английский
Emerging molecular therapies in the treatment of bladder cancer
Exploration of Targeted Anti-tumor Therapy,
Год журнала:
2024,
Номер
5(5), С. 1135 - 1154
Опубликована: Авг. 29, 2024
Bladder
cancer
is
a
leading
type
in
men.
The
complexity
of
treatment
late-stage
bladder
after
systemic
spread
through
the
lymphatic
system
highlights
importance
modulating
disease-free
progression
as
early
possible
staging.
With
current
therapies
relying
on
previous
standards,
such
platinum-based
chemotherapeutics
and
immunomodulation
with
Bacillus
Calmette-Guerin,
researchers,
clinicians
are
looking
for
targeted
to
stop
at
its
source
progression.
A
new
era
molecular
that
target
specific
features
upregulated
cell
lines
surfacing,
which
may
be
able
provide
patients
better
control
disease
Here,
we
discuss
multiple
emerging
including
immune
checkpoint
inhibitors
programmed
death
protein
1
(PD-1)/programmed
ligand
(PD-L1)
pathway,
antibody-drug
conjugates,
modulation
phosphoinositide
3-kinase
(PI3K)/protein
kinase
B
(AKT)/mammalian
rapamycin
(mTOR)
proliferation
chimeric
antigen
receptor
T-cell
therapy,
fibroblast
growth
factor
targeting.
Together,
these
modern
treatments
potentially
promising
results
possibility
increasing
remission
survival
rates.
Язык: Английский
Evolving Treatment Landscape of Frontline Therapy for Metastatic Urothelial Carcinoma: Current Insights and Future Perspectives
Cancers,
Год журнала:
2024,
Номер
16(23), С. 4078 - 4078
Опубликована: Дек. 5, 2024
Cisplatin-based
chemotherapy
has
long
been
the
standard
first-line
(1L)
treatment
for
metastatic
urothelial
carcinoma
(mUC).
However,
up
to
50%
of
patients
with
mUC
may
be
ineligible
cisplatin
owing
comorbidities,
necessitating
alternative
primary
options.
Immune
checkpoint
inhibitors
(ICIs)
have
emerged
as
a
vital
those
unable
receive
cisplatin.
Nevertheless,
prognosis
advanced
UC
remains
dire
and
challenges
persist
in
optimizing
1L
therapy.
Recent
medical
advancements
redirected
attention
towards
innovative
drug
combinations
mUC.
The
combination
enfortumab
vedotin
(EV)
pembrolizumab
shown
significantly
improved
overall
progression-free
survival
rates
compared
alone.
This
can
used
who
are
cisplatin-ineligible
or
require
alternatives
chemotherapy.
While
platinum-based
continues
essential
many
patients,
approval
EV
treatments
signifies
major
breakthrough
cancer
care.
These
therapies
offer
enhanced
outcomes
terms
response
highlight
increasing
relevance
ICI-containing
regimens
frontline
review
provides
an
exhaustive
overview
current
landscape
explores
new
therapeutic
strategies,
aim
facilitating
clinical
decision-making
guiding
strategies
Язык: Английский